NEW YORK (GenomeWeb) – Biocept reported after the close of the market on Tuesday that its fourth quarter revenues rose nearly 500 percent year over year.

For the three months ended Dec. 31, the company's total revenues rose to $1.3 million from $218,283 in the prior-year quarter. Within its overall revenue, $1.2 million came from commercial testing and another $70,000 was from the firm's development services.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.